| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $773K | — | -44.1% |
| SG&A Expense | $1.9M | — | +92.6% |
| Operating Income | -$2.7M | — | -13.0% |
| Interest Expense | $100K | — | — |
| Net Income | -$3.0M | — | -24.7% |
| EPS (Diluted) | -$4.00 | — | -455.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $10.3M | +1612.2% | — |
| Current Assets | $10.4M | +1399.4% | +654.1% |
| Total Assets | $12.5M | +346.9% | +256.1% |
| Current Liabilities | $5.8M | +44.1% | +107.8% |
| Total Liabilities | $5.8M | +43.5% | +104.2% |
| Stockholders' Equity | $6.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.2M | — | +25.4% |
| Financing Cash Flow | $10.9M | — | — |
| +923.3% |